The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer

Cantharidin, one of the active components of mylabris, is believed to have antitumor activity. Cantharidin selectively inhibits protein phosphatase 2A (PP2A), which can repress multiple oncogenic kinases (ERK, JNK, PKC, and NF-κB). Researches in vitro have shown that cantharidin suppresses cell viab...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Meng-Dan, Liu, Lu, Wu, Meng-Yao, Jiang, Min, Shou, Liu-Mei, Wang, Wen-Jie, Wu, Jing, Zhang, Yan, Gong, Fei-Ran, Chen, Kai, Tao, Min, Zhi, Qiaoming, Li, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255842/
https://www.ncbi.nlm.nih.gov/pubmed/30478299
http://dx.doi.org/10.1038/s41389-018-0102-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255842/
https://www.ncbi.nlm.nih.gov/pubmed/30478299
http://dx.doi.org/10.1038/s41389-018-0102-2

Ejemplares similares